Gapping up
In reaction to strong earnings/guidance: JOUT +1.4%
M&A news: GMCR +74.8% (to be acquired by a JAB Holding Company-Led Investor Group for $92/share in cash), WIBC +11.1% (to be acquired by BBCN Bancorp (BBCN) for $13.00/share , or ~$1.0 bln in a 'merger of equals'), HMIN +5.7% (to be acquired by BTG Hotels for $35.80 per ADS), DATE +2.9% (to be acquired by Parent for $7.56/share)
Other news: NETE +37.9% (cont pre-mkt vol), SODA +14.8% (spikes in response to buyout of peer Green Mountain), GAI +13.6% (announces "Golng Private" transaction for $8.85 per share), ASTI +10.8% (cont pre-mkt vol), CTIC +9.5% (reports Phase 3 results treatment with Pacritinib support the effectiveness of pacritinib across intermediate or high-risk myelofibrosis patient subgroups analyzed ), BLCM +9.2% (reports results BPX-501; significant reductions in time to hospital discharge and re-hospitalizations), IDRA +6.8% (reports positive data from ongoing Phase 1/2 clinical trial of IMO-8400), ARWR +6.3% (presents data showing that in chronically HBV-infected chimpanzees treated with ARC-520 in combination with nucleoside analogs, 78% exhibited signs of immune reactivation), SWHC +4.8% (NY Post discusses recent surge in gun sales following California shootings), TGTX +4.1% (reports combination of TG-1101 plus TGR-1202 continues to demonstrate a favorable safety profile), XLRN +3.7% (Acceleron Pharma and Celgene (CELG) New Results from an Investigational Study with Luspatercept; increased hemoglobin levels and generated transfusion independence), AA +1.4% (Barron's profiles positive view on Alcoa (AA)), BUD +1.4% (cont pre-mkt vol), QGEN +1.2% (still checking), SGEN +1.2% (provided study updates at ASH)
Analyst comments: ISLE +4.6% (upgraded to Buy from Hold at Stifel), MCC +2.5% (upgraded to Outperform from Mkt Perform at Keefe Bruyette), LLY +1.3% (upgraded to Buy from Hold at Deutsche Bank), ABT +1.2% (upgraded to Buy from Hold at Jefferies
)
In reaction to strong earnings/guidance: JOUT +1.4%
M&A news: GMCR +74.8% (to be acquired by a JAB Holding Company-Led Investor Group for $92/share in cash), WIBC +11.1% (to be acquired by BBCN Bancorp (BBCN) for $13.00/share , or ~$1.0 bln in a 'merger of equals'), HMIN +5.7% (to be acquired by BTG Hotels for $35.80 per ADS), DATE +2.9% (to be acquired by Parent for $7.56/share)
Other news: NETE +37.9% (cont pre-mkt vol), SODA +14.8% (spikes in response to buyout of peer Green Mountain), GAI +13.6% (announces "Golng Private" transaction for $8.85 per share), ASTI +10.8% (cont pre-mkt vol), CTIC +9.5% (reports Phase 3 results treatment with Pacritinib support the effectiveness of pacritinib across intermediate or high-risk myelofibrosis patient subgroups analyzed ), BLCM +9.2% (reports results BPX-501; significant reductions in time to hospital discharge and re-hospitalizations), IDRA +6.8% (reports positive data from ongoing Phase 1/2 clinical trial of IMO-8400), ARWR +6.3% (presents data showing that in chronically HBV-infected chimpanzees treated with ARC-520 in combination with nucleoside analogs, 78% exhibited signs of immune reactivation), SWHC +4.8% (NY Post discusses recent surge in gun sales following California shootings), TGTX +4.1% (reports combination of TG-1101 plus TGR-1202 continues to demonstrate a favorable safety profile), XLRN +3.7% (Acceleron Pharma and Celgene (CELG) New Results from an Investigational Study with Luspatercept; increased hemoglobin levels and generated transfusion independence), AA +1.4% (Barron's profiles positive view on Alcoa (AA)), BUD +1.4% (cont pre-mkt vol), QGEN +1.2% (still checking), SGEN +1.2% (provided study updates at ASH)
Analyst comments: ISLE +4.6% (upgraded to Buy from Hold at Stifel), MCC +2.5% (upgraded to Outperform from Mkt Perform at Keefe Bruyette), LLY +1.3% (upgraded to Buy from Hold at Deutsche Bank), ABT +1.2% (upgraded to Buy from Hold at Jefferies
)